DERMIRA, INC. (NASDAQ:DERM) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August7, 2017, Dermira,Inc. issued a press release announcing its financial results for the quarter ended June30, 2017. The press release is being furnished as Exhibit99.1.
| Item 2.02 | Financial Statements and Exhibits. |
(d)Exhibits.
|
ExhibitNo. |
Description |
| 99.1 | Dermira Inc. Press Release dated August 7, 2017 |
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Dermira, Inc. ExhibitEX-99.1 2 d439594dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update – sBLA for CIMZIA® (certolizumab pegol) submitted to FDA – Submission of NDA for glycopyrronium tosylate on schedule for second half of 2017 – Guidance for Phase 3 olumacostat glasaretil topline results updated to first quarter of 2018 MENLO PARK,…To view the full exhibit click here
About DERMIRA, INC. (NASDAQ:DERM)
Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.